Molenaar, R., Radivoyevitch, T., Nagata, Y., Khurshed, M., Przychodzen, B., Makishima, H., … Maciejewski, J. (2018). IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-2796 (Original work published 2018)